News

Recombinant and microbial P450 and glycosylating technology have been developed for accessing metabolites at mg to 100s grams scale, the company said. These enzymes, which resemble human systems,

As per the agreement, Tris will use its proprietary technology and will develop up to six new drug applications (NDAs), on behalf of Vernalis. Tris will undertake and

Uceris is a locally acting corticosteroid that utilizes proprietary MMX multi-matrix system technology to enable controlled release and distribution of budesonide throughout the length of the colon. The

The primary objective of the study is to evaluate the safety and tolerability of SGX201 and assess the preliminary efficacy of SGX201 for prevention of symptoms of acute

Tony Sedgwick has joined the company in September 2011 and has extensive experience from European life science companies including more than fifteen years at Roche. Prior to joining

Tadalafil is an FDA-approved drug used as treatment for male erectile dysfunction (ED). The active drug ingredient is not listed on the label for these products. Tadafil could

The new strategic drug development organization was designated to help biopharma companies design and implement drug development strategies. The strategies take into account the Asia product commercialization opportunity

In addition, the company is also planning European registration Phase 3 clinical trial of Arikace in Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections. The randomized

The company will supply a range of APIs from its Bangalore facility to its customers in markets like the US, Europe, South East Asia, Latin America, Canada and